Initiating high-efficacy monoclonal antibody therapy before age 18 may reduce long-term disability in pediatric-onset multiple sclerosis.

Nanocurcumin was linked to better disability scores in small RRMS trials, but researchers say larger studies are needed.

Sanofi/Ad Scientiam presented an interim analysis from the ongoing MS-DETECT (NCT05816122) study, showing that Microsoft (MS) ...

Daily propionic acid supplements lowered levels of a nerve damage marker in people with MS, but clinical benefits remain ...

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant ...

A review of a disability benefit is not expected to make "crude proposals" on changes to claimants' payments, the minister ...

A single-center observational cohort (n=116; 81% RRMS) receiving ocrelizumab from 2018–2023 enabled longitudinal tracking of IgG, IgA, and IgM across treatment cycles. Serial dosing produced gradual ...

MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE ...

Anil Menon, a NASA astronaut of Indian descent, is set to embark on an eight-month mission to the International Space Station ...

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with ...

(Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and ...

Retailers have warned that an incoming Re-Turnstyle deposit scheme in the North, which will pay higher rates per bottle, will ...